# A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age.

> **NCT02570126** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1236 (actual)

## Conditions studied

- Chicken-pox Illness (Varicella Virus Disease)
- Chickenpox

## Interventions

- **BIOLOGICAL:** Varilrix HSA-free
- **BIOLOGICAL:** Varilrix™

## Key facts

- **NCT ID:** NCT02570126
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-13
- **Primary completion:** 2016-10-25
- **Final completion:** 2016-10-25
- **Target enrollment:** 1236 (ACTUAL)
- **Last updated:** 2019-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02570126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02570126, "A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02570126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*